Oragenics Announces Proposed Public Offering
2024年2月28日 - 6:33AM
ビジネスワイヤ(英語)
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”), a company focused on developing unique, intranasal
nanoparticle pharmaceuticals for the treatment of neurological
disorders, today announced that it intends to offer to sell shares
of its common stock (and/or pre-funded warrants to purchase shares
of common stock (“Pre-Funded Warrants”) in lieu thereof) in an
underwritten public offering. The Company expects to grant the
underwriters a 45-day option to purchase up to an additional 15% of
the number of shares of common stock and/or Pre-Funded Warrants
sold in this offering to cover over-allotments, if any. The
offering is subject to market conditions and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
ThinkEquity and Laidlaw & Company (UK) Ltd. are acting as
joint book-running managers for the offering.
The Company intends to use the net proceeds from the offering to
fund the continued development of ONP-002, which is a unique
neurosteroid drug compound intended to treat mild traumatic brain
injuries also known as concussions, and for general corporate
purposes and working capital.
The securities will be offered and sold pursuant to a shelf
registration statement on Form S-3 (File No. 333-269225), including
a base prospectus, filed with the U.S. Securities and Exchange
Commission (the “SEC”) on January 13, 2023 and declared effective
on January 25, 2023. The offering will be made only by means of a
written prospectus. A preliminary prospectus supplement and
accompanying prospectus describing the terms of the offering has
been or will be filed with the SEC and will be available on its
website at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to the offering
may also be obtained from the offices of ThinkEquity, 17 State
Street, 41st Floor, New York, New York 10004. Before investing in
this offering, interested parties should read in their entirety the
preliminary prospectus supplement and the accompanying prospectus
and the other documents that the Company has filed with the SEC
that are incorporated by reference in such preliminary prospectus
supplement and the accompanying prospectus, which provide more
information about the Company and such offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology company focused
on nasal delivery of pharmaceutical medications in neurology and
fighting infectious diseases, including drug candidates for
treating mild traumatic brain injury (mTBI), also known as
concussion, and for treating Niemann Pick Disease Type C (NPC), as
well as proprietary powder formulation and an intranasal delivery
device. For more information, please visit www.oragenics.com.
Forward-Looking
Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including without
limitation statements regarding the ability of the Company to
successfully complete the announced public offering and the ability
of the Company to timely and successfully undertake Phase II
clinical trial using its novel drug - device combination for the
treatment of mild Traumatic Brain Injury. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to: the Company’s ability to advance the development of
its product candidates, including the neurology assets, under the
timelines and in accord with the milestones it projects; the
Company’s ability to raise capital and obtain funding, non-dilutive
or otherwise, for the development of its product candidates; the
regulatory application process, research and development stages,
and future clinical data and analysis relating to its product
candidates, including any meetings, decisions by regulatory
authorities, such as the FDA and investigational review boards,
whether favorable or unfavorable; the Company’s ability to obtain,
maintain and enforce necessary patent and other intellectual
property protection; the nature of competition and development
relating to concussion treatments; the Company’s expectations as to
the outcome of preclinical studies and clinical trials and the
potential benefits, activity, effectiveness and safety of its
product candidates including as to administration, transmission,
manufacturing, storage and distribution; and general economic and
market conditions and risks, as well as other uncertainties
described in our filings with the Securities and Exchange
Commission. All information set forth is as of the date hereof
unless otherwise indicated. You should consider these factors in
evaluating the forward-looking statements included and not place
undue reliance on such statements. We do not assume any obligation
to publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227587815/en/
Oragenics, Inc. Janet Huffman, Chief Financial Officer
813-286-7900 jhuffman@oragenics.com
Oragenics (AMEX:OGEN)
過去 株価チャート
から 4 2024 まで 5 2024
Oragenics (AMEX:OGEN)
過去 株価チャート
から 5 2023 まで 5 2024